Medical technology company Becton, Dickinson and Co. is partnering with life sciences company Labcorp to develop cytometry-based companion diagnostics that can be used to match patients with treatments.
The collaboration between the two companies will encompass the entire process of cytometry-based companion diagnostics, from early development to the FDA approval process. Flow cytometry tests can be helpful for cancer patients to ensure the best treatments and cost savings, according to the Aug. 9 press release.
"Flow cytometry is a trusted and powerful tool for analyzing cells to better understand disease, and it has tremendous untapped potential as a companion diagnostic in oncology and other therapeutic areas," Bill Hanlon, PhD, chief scientific officer of Labcorp Drug Development, said. "This strategic collaboration with BD, a pioneer and global leader in flow cytometry, is an exciting step toward increasing adoption and ultimately bringing innovative new companion diagnostics to market to help identify patients who could benefit most from appropriate treatments."